Business Description
Biogen Inc
NAICS : 325412
SIC : 2834
ISIN : US09062X1037
Compare
Compare
Traded in other countries / regions
BIIB.ArgentinaBIIB.AustriaBIIB34.BrazilIDP.GermanyBIIB.MexicoBIIB.Switzerland0R1B.UKBIIB.USA IPO Date
1991-09-17Description
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.76 | |||||
| Equity-to-Asset | 0.56 | |||||
| Debt-to-Equity | 0.48 | |||||
| Debt-to-EBITDA | 1.48 | |||||
| Interest Coverage | 11.43 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 4.62 | |||||
| Beneish M-Score | -2.37 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -3.2 | |||||
| 3-Year EBITDA Growth Rate | -10.5 | |||||
| 3-Year EPS without NRI Growth Rate | -12.7 | |||||
| 3-Year FCF Growth Rate | -38.9 | |||||
| 3-Year Book Growth Rate | 6.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 4.21 | |||||
| Future 3-5Y Total Revenue Growth Rate | -5.68 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 27.64 | |||||
| 9-Day RSI | 37.46 | |||||
| 14-Day RSI | 45.62 | |||||
| 6-1 Month Momentum % | -5.61 | |||||
| 12-1 Month Momentum % | 41.04 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.24 | |||||
| Quick Ratio | 2.81 | |||||
| Cash Ratio | 1.67 | |||||
| Days Inventory | 217.28 | |||||
| Days Sales Outstanding | 73.5 | |||||
| Days Payable | 73.41 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 6.1 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 78.35 | |||||
| Operating Margin % | 27.49 | |||||
| Net Margin % | 30.99 | |||||
| ROE % | 24.82 | |||||
| ROA % | 12.76 | |||||
| ROIC % | 14.1 | |||||
| ROC (Joel Greenblatt) % | 78.82 | |||||
| ROCE % | 18.96 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 13.87 | |||||
| Forward PE Ratio | 19.61 | |||||
| PE Ratio without NRI | 13.87 | |||||
| Shiller PE Ratio | 14.49 | |||||
| Price-to-Owner-Earnings | 16.43 | |||||
| PS Ratio | 4.3 | |||||
| PB Ratio | 3.13 | |||||
| Price-to-Tangible-Book | 6.94 | |||||
| Price-to-Free-Cash-Flow | 30.58 | |||||
| Price-to-Operating-Cash-Flow | 25.89 | |||||
| EV-to-EBIT | 11.41 | |||||
| EV-to-Forward-EBIT | 17.31 | |||||
| EV-to-EBITDA | 10.03 | |||||
| EV-to-Forward-EBITDA | 14.17 | |||||
| EV-to-Revenue | 4.43 | |||||
| EV-to-Forward-Revenue | 4.68 | |||||
| EV-to-FCF | 31.53 | |||||
| Price-to-Projected-FCF | 0.95 | |||||
| Price-to-Median-PS-Value | 0.86 | |||||
| Price-to-Graham-Number | 2.07 | |||||
| Earnings Yield (Greenblatt) % | 8.76 | |||||
| Forward Rate of Return (Yacktman) % | -1.57 |
Balance Sheet Breakdown
Cashflow Statement Breakdown
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BIIB
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
Biogen Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 10,104.6 | ||
| EPS (TTM) ($) | 21.54 | ||
| Beta | 0.1 | ||
| Volatility % | 42.48 | ||
| 14-Day RSI | 45.62 | ||
| 14-Day ATR ($) | 5.776534 | ||
| 20-Day SMA ($) | 308.592 | ||
| 12-1 Month Momentum % | 41.04 | ||
| 52-Week Range ($) | 188.535 - 319.74 | ||
| Shares Outstanding (Mil) | 144.74 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Biogen Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Biogen Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Biogen Inc Frequently Asked Questions
What is Biogen Inc(BIIB)'s stock price today?
The current price of BIIB is $298.66. The 52 week high of BIIB is $319.74 and 52 week low is $188.54.
When is next earnings date of Biogen Inc(BIIB)?
The next earnings date of Biogen Inc(BIIB) is 2023-07-20 Est..
Does Biogen Inc(BIIB) pay dividends? If so, how much?
Biogen Inc(BIIB) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
